An Orthotopic Model of Metastatic Nasopharyngeal Carcinoma and Its Application in Elucidating a Therapeutic Target That Inhibits Metastasis

Genes and Cancer

Volumn 2, Issue 11, 2011, Pages 1023-1033

  Smith, Pamela A ^a   Merritt, David ^b   Barr, Leah ^a   Thorley Lawson, David A ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

metastasis; mTOR; nasopharyngeal carcinoma; orthotopic xenograft

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENESIS; DISSEMINATED CANCER; DRUG TARGETING; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; METASTASIS; METASTASIS INHIBITION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84868649424     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912440878     Document Type: Article

References (52)

1. Parkin DM,Muir CS.Cancer incidence in five continents: comparability and quality of data.IARC Sci Publ. 1992; (120): 45-173.
2. Ayadi W,Khabir A,Hadhri-Guiga B, et al.North African and Southeast Asian nasopharyngeal carcinomas: between the resemblance and the dissemblance.Bull Cancer. 2010;97 (4): 475-82.
3. Toumi N,Frikha M,Siala W, et al.Juvenile nasopharyngeal carcinoma: anatomoclinic, biologic, therapeutic and evolutive aspects.Bull Cancer. 2010;97 (4): 427-33.
4. Lee AW,Sze WM,Au JS, et al.Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience.Int J Radiat Oncol Biol Phys. 2005;61 (4): 1107-16.
5. O'Sullivan B.Nasopharynx cancer: therapeutic value of chemoradiotherapy.Int J Radiat Oncol Biol Phys. 2007;69 (2 Suppl): S118-21.
6. Skinner DW,Van Hasselt CA,Tsao SY.Nasopharyngeal carcinoma: modes of presentation.Ann Otol Rhinol Laryngol. 1991;100 (7): 544-51.
7. Gullo C,Low WK,Teoh G.Association of Epstein-Barr virus with nasopharyngeal carcinoma and current status of development of cancer-derived cell lines.Ann Acad Med Singapore. 2008;37 (9): 769-77.
8. Hui AB,Yue S,Shi W, et al.Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009;15 (11): 3716-24.
9. Kato H,Ito E,Shi W, et al.Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.Clin Cancer Res. 2010;16 (3): 898-911.
10. Ke X,Yang YC,Hong SL.EBV-LMP1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666-1 xenograft model.Med Oncol. 2011;28 (Suppl 1): S326-32.
11. Liu T,Ding Y,Xie W, et al.An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res. 2007;13 (13): 3960-7.
12. Lum CT,Liu X,Sun RW, et al.Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro. Cancer Lett. 2010;294 (2): 159-66.
13. Dubrulle F,Souillard R,Hermans R.Extension patterns of nasopharyngeal carcinoma.Eur Radiol. 2007;17 (10): 2622-30.
14. Teo PM,Kwan WH,Lee WY,Leung SF,Johnson PJ.Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma.Cancer. 1996;77 (12): 2423-31.
15. Sham JS,Cheung YK,Chan FL,Choy D.Nasopharyngeal carcinoma: pattern of skeletal metastases.Br J Radiol. 1990;63 (747): 202-5.
16. Nicholls JM.Nasopharyngeal carcinoma: classification and histologic appearances.Adv Anat Pathol. 1997;4 (2): 71-84.
17. Lamb J.The Connectivity Map: a new tool for biomedical research.Nat Rev Cancer. 2007;7 (1): 54-60.
18. Lamb J,Crawford ED,Peck D, et al.The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.Science. 2006;313 (5795): 1929-35.
19. Hennessy BT,Smith DL,Ram PT,Lu Y,Mills GB.Exploiting the PI3K/AKT pathway for cancer drug discovery.Nat Rev Drug Discov. 2005;4 (12): 988-1004.
20. Larue L,Bellacosa A.Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.Oncogene. 2005;24 (50): 7443-54.
21. Sabatini DM.mTOR and cancer: insights into a complex relationship.Nat Rev Cancer. 2006;6 (9): 729-34.
22. Weinberg RA.Mechanisms of malignant progression.Carcinogenesis. 2008;29 (6): 1092-5.
23. Cui C,Liu L,Ma J, et al.Trigeminal nerve palsy in nasopharyngeal carcinoma: correlation between clinical findings and magnetic resonance imaging.Head Neck. 2009;31 (6): 822-8.
24. Kim EK,Yun SJ,Ha JM, et al.Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.Oncogene. 2011;30 (26): 2954-63.
25. Graff JR,Konicek BW,Carter JH,Marcusson EG.Targeting the eukaryotic translation initiation factor 4E for cancer therapy.Cancer Res. 2008;68 (3): 631-4.
26. Sarbassov DD,Guertin DA,Ali SM,Sabatini DM.Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.Science. 2005;307 (5712): 1098-101.
27. Chiang GG,Abraham RT.Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.J Biol Chem. 2005;280 (27): 25485-90.
28. Rosner M,Siegel N,Valli A,Fuchs C,Hengstschlager M.mTOR phosphorylated at S2448 binds to raptor and rictor.Amino Acids. 2010;38 (1): 223-8.
29. Sham JS,Cheung YK,Choy D,Chan FL,Leong L.Nasopharyngeal carcinoma: CT evaluation of patterns of tumor spread.AJNR Am J Neuroradiol. 1991;12 (2): 265-70.
30. Cheng SH,Jian JJ,Tsai SY, et al.Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy.Int J Radiat Oncol Biol Phys. 2000;48 (5): 1323-30.
31. Yamashita S,Kondo M,Hashimoto S.Squamous cell carcinoma of the nasopharynx: an analysis of failure patterns after radiation therapy.Acta Radiol Oncol. 1985;24 (4): 315-20.
32. Cvitkovic E,Bachouchi M,Boussen H, et al.Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases.J Clin Oncol. 1993;11 (12): 2434-42.
33. Ma XM,Blenis J.Molecular mechanisms of mTOR-mediated translational control.Nat Rev Mol Cell Biol. 2009;10 (5): 307-18.
34. Razak AR,Siu LL,Liu FF,Ito E,O'Sullivan B,Chan K.Nasopharyngeal carcinoma: the next challenges.Eur J Cancer. 2010;46 (11): 1967-78.
35. Kwong DL,Sham JS,Au GK, et al.Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.J Clin Oncol. 2004;22 (13): 2643-53.
36. Geara FB,Sanguineti G,Tucker SL, et al.Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival.Radiother Oncol. 1997;43 (1): 53-61.
37. Ma BB,Lui VW,Hui EP, et al.The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.Invest New Drugs. 2010;28 (4): 413-20.
38. Liu LZ,Zhou XD,Qian G,Shi X,Fang J,Jiang BH.AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.Cancer Res. 2007;67 (13): 6325-32.
39. Peng DJ,Wang J,Zhou JY,Wu GS.Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.Biochem Biophys Res Commun. 2010;394 (3): 600-5.
40. Mei YP,Zhou JM,Wang Y, et al.Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells.Cell Cycle. 2007;6 (11): 1379-85.
41. Fendri A,Khabir A,Mnejja W, et al.PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma.Cancer Sci. 2009;100 (11): 2034-9.
42. Chen J,Hu CF,Hou JH, et al.Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma.J Transl Med. 2010;8:30.
43. Fasolo A,Sessa C.Current and future directions in mammalian target of rapamycin inhibitors development.Expert Opin Investig Drugs. 2011;20 (3): 381-94.
44. Shah KM,Young LS.Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma.Clin Microbiol Infect. 2009;15 (11): 982-8.
45. Moody CA,Scott RS,Amirghahari N, et al.Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A.J Virol. 2005;79 (9): 5499-506.
46. Scholle F,Bendt KM,Raab-Traub N.Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt.J Virol. 2000;74 (22): 10681-9.
47. Shair KH,Schnegg CI,Raab-Traub N.Epstein-Barr virus latent membrane protein-1 effects on junctional plakoglobin and induction of a cadherin switch.Cancer Res. 2009;69 (14): 5734-42.
48. Pegtel DM,Subramanian A,Sheen TS,Tsai CH,Golub TR,Thorley-Lawson DA.Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis.J Virol. 2005;79:15430-42.
49. Hochberg D,Souza T,Catalina M,Sullivan JL,Luzuriaga K,Thorley-Lawson DA.Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.J Virol. 2004;78 (10): 5194-204.
50. Pomeroy SL,Tamayo P,Gaasenbeek M, et al.Prediction of central nervous system embryonal tumour outcome based on gene expression.Nature. 2002;415 (6870): 436-42.
51. Cheung ST,Huang DP,Hui AB, et al.Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus.Int J Cancer. 1999;83 (1): 121-6.
52. Glaser R,Zhang HY,Yao KT, et al.Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas.Proc Natl Acad Sci U S A. 1989;86 (23): 9524-8.